Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Cochlear Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Cochlear kazanç ve gelirin sırasıyla yıllık 11.5% ve 8.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 11.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 24.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

11.5%

Kazanç büyüme oranı

11.5%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	16.5%
Gelir büyüme oranı	8.2%
Gelecekteki özkaynak getirisi	24.9%
Analist kapsamı	Good
Son güncelleme	24 Sep 2024

Gelecekteki son büyüme güncellemeleri

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Aug 16

Recent updates

Cochlear Limited's (ASX:COH) Shareholders Might Be Looking For Exit

Sep 19

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Aug 16

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 04

Cochlear (ASX:COH) Could Be Struggling To Allocate Capital

Sep 12

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Jun 05

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

Apr 05

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Mar 04

Is Cochlear (ASX:COH) A Risky Investment?

Dec 19

Is Cochlear Limited (ASX:COH) Worth AU$205 Based On Its Intrinsic Value?

Nov 16

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Oct 25

Should Shareholders Reconsider Cochlear Limited's (ASX:COH) CEO Compensation Package?

Oct 11

Cochlear's (ASX:COH) Upcoming Dividend Will Be Larger Than Last Year's

Aug 28

Here's Why Cochlear (ASX:COH) Can Manage Its Debt Responsibly

Aug 23

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Jul 16

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

May 19

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Apr 09

Estimating The Intrinsic Value Of Cochlear Limited (ASX:COH)

Feb 04

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Dec 24

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

Oct 30

This Is Why We Think Cochlear Limited's (ASX:COH) CEO Might Get A Pay Rise Approved By Shareholders

Oct 12

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

Oct 06

Returns On Capital Signal Tricky Times Ahead For Cochlear (ASX:COH)

Aug 16

Cochlear (ASX:COH) Has A Pretty Healthy Balance Sheet

Jun 24

A Look At The Intrinsic Value Of Cochlear Limited (ASX:COH)

May 17

There Are Reasons To Feel Uneasy About Cochlear's (ASX:COH) Returns On Capital

Apr 29

These 4 Measures Indicate That Cochlear (ASX:COH) Is Using Debt Reasonably Well

Mar 20

Kazanç ve Gelir Büyüme Tahminleri

ASX:COH - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2027	2,924	532	491	604	13
6/30/2026	2,685	470	412	523	14
6/30/2025	2,466	423	407	522	14
6/30/2024	2,236	357	299	389	N/A
3/31/2024	2,193	354	317	410	N/A
12/31/2023	2,149	350	335	430	N/A
9/30/2023	2,043	326	301	396	N/A
6/30/2023	1,936	301	267	362	N/A
3/31/2023	1,824	281	263	352	N/A
12/31/2022	1,713	261	259	341	N/A
9/30/2022	1,681	275	279	359	N/A
6/30/2022	1,648	289	299	377	N/A
3/31/2022	1,612	273	266	340	N/A
12/31/2021	1,575	257	233	304	N/A
9/30/2021	1,536	291	216	285	N/A
6/30/2021	1,498	324	199	265	N/A
3/31/2021	1,403	82	-52	34	N/A
12/31/2020	1,308	-160	-302	-198	N/A
9/30/2020	1,314	-199	-295	-178	N/A
6/30/2020	1,321	-238	-288	-158	N/A
3/31/2020	1,400	34	-80	50	N/A
12/31/2019	1,479	306	128	259	N/A
9/30/2019	1,453	291	155	277	N/A
6/30/2019	1,427	277	181	296	N/A
3/31/2019	1,422	270	217	313	N/A
12/31/2018	1,418	264	252	330	N/A
9/30/2018	1,391	255	230	294	N/A
6/30/2018	1,364	246	208	258	N/A
3/31/2018	1,329	234	N/A	254	N/A
12/31/2017	1,294	223	N/A	250	N/A
9/30/2017	1,274	223	N/A	255	N/A
6/30/2017	1,254	224	N/A	260	N/A
3/31/2017	1,218	215	N/A	237	N/A
12/31/2016	1,182	206	N/A	214	N/A
9/30/2016	1,156	198	N/A	199	N/A
6/30/2016	1,131	189	N/A	185	N/A
3/31/2016	1,088	179	N/A	179	N/A
12/31/2015	1,045	168	N/A	172	N/A
9/30/2015	986	157	N/A	181	N/A
6/30/2015	926	146	N/A	189	N/A
3/31/2015	899	145	N/A	178	N/A
12/31/2014	872	144	N/A	168	N/A
9/30/2014	839	119	N/A	140	N/A
6/30/2014	805	94	N/A	111	N/A
3/31/2014	769	85	N/A	93	N/A
12/31/2013	732	76	N/A	75	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: COH 'nin tahmini kazanç büyümesi (yıllık 11.5% ) tasarruf oranının ( 2.4% ) üzerindedir.

Kazançlar ve Piyasa: COH şirketinin kazançlarının (yıllık 11.5% ) Australian pazarından (yıllık 12.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: COH şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: COH şirketinin gelirinin (yıllık 8.2% ) Australian pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: COH şirketinin gelirinin (yıllık 8.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: COH 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 24.9 %)

Cochlear Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Price target increased by 7.0% to AU$272

Cochlear Limited Provides Earnings Outlook for the Year 2023

Cochlear Limited Provides Earnings Guidance for the Fiscal Year 2022

Recent updates

Now 20% overvalued

Cochlear Limited's (ASX:COH) Shareholders Might Be Looking For Exit

CEO, MD exercised options and sold AU$613k worth of stock

Stu Sayers to Appoint as President, Asia Pacific & Latin America of Cochlear Limited, Effective from 1 January 2025

Upcoming dividend of AU$2.10 per share

Final dividend of AU$2.10 announced

Cochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended June 30, 2024, Payable on October 10, 2024

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Full year 2024 earnings: EPS misses analyst expectations

Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.

Investors Could Be Concerned With Cochlear's (ASX:COH) Returns On Capital

Cochlear Limited Appoints Caroline Clarke as Non-Executive Director, Effective from 2 September 2024

Cochlear Limited Announces Executive Changes

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Cochlear Limited Announces Company Secretary Changes

Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Upcoming dividend of AU$2.00 per share

First half dividend increased to AU$2.00

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

First half 2024 earnings: EPS in line with expectations, revenues disappoint

Price target increased by 7.0% to AU$272

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

Cochlear (ASX:COH) Could Be Struggling To Allocate Capital

Upcoming dividend of AU$1.75 per share at 1.2% yield

Cochlear Limited Introduces Next Generation Cochlear Osia System with Ability to Have MRI at 3.0 T

Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Cochlear Limited Announces Andrew Denver, Non-Executive Director Intention to Retire At AGM to Be Held on 17 October 2023

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

Upcoming dividend of AU$1.55 per share at 1.3% yield

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Cochlear Limited Provides Earnings Outlook for the Year 2023

Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.

Is Cochlear (ASX:COH) A Risky Investment?

Cochlear Limited, Annual General Meeting, Oct 17, 2023

Is Cochlear Limited (ASX:COH) Worth AU$205 Based On Its Intrinsic Value?

FDA Approves Cochlear Limited's Nucleus 8 Sound Processor, Smaller, Smarter, Better Connected Cochlear Implant Technology

Key Executive recently bought AU$97k worth of stock

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Should Shareholders Reconsider Cochlear Limited's (ASX:COH) CEO Compensation Package?

Upcoming dividend of AU$1.45 per share

Cochlear's (ASX:COH) Upcoming Dividend Will Be Larger Than Last Year's

Here's Why Cochlear (ASX:COH) Can Manage Its Debt Responsibly

Full year 2022 earnings: EPS misses analyst expectations

Cochlear Announces Final Dividend Payable on 17 October 2022

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Cochlear Limited Appoints Karen Penrose to Board, Effective on 1 July 2022

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

Cochlear Limited, Annual General Meeting, Oct 18, 2022

Cochlear Limited to Report First Half, 2023 Results on Feb 15, 2023

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Upcoming dividend of AU$1.55 per share

Investor sentiment improved over the past week

First half 2022 earnings: EPS and revenues exceed analyst expectations

Cochlear Limited Announces Interim Dividend Expected to Be Payable on 21 April 2022

Estimating The Intrinsic Value Of Cochlear Limited (ASX:COH)

FDA Approves Cochlear Nucleus Implants for Unilateral Hearing Loss/Single-Sided Deafness

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Independent Non-Executive Director recently bought AU$56k worth of stock

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

This Is Why We Think Cochlear Limited's (ASX:COH) CEO Might Get A Pay Rise Approved By Shareholders

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

Cochlear Limited Advises of US Patent Infringement Complaint

Upcoming dividend of AU$1.40 per share

CEO, MD exercised options and sold AU$295k worth of stock

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear Implantation

Independent Non-Executive Director recently bought AU$94k worth of stock